Hanson & Doremus Investment Management Has $2.02 Million Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Hanson & Doremus Investment Management reduced its holdings in Johnson & Johnson by 13.0%, ending the second quarter with 13,251 shares valued at approximately $2.02 million.
• Johnson & Johnson reported a quarterly earnings per share (EPS) of $2.77, exceeding analyst expectations, and a revenue of $23.74 billion, up 5.8% year-over-year.
• Recently, Johnson & Johnson raised its dividend payout to $1.30 per share, representing an annualized yield of 2.9% with a payout ratio of 55.61%.

Hanson & Doremus Investment Management lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 13.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,251 shares of the company's stock after selling 1,976 shares during the period. Hanson & Doremus Investment Management's holdings in Johnson & Johnson were worth $2,024,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in JNJ. R.H. Investment Group LLC grew its position in Johnson & Johnson by 0.3% during the second quarter. R.H. Investment Group LLC now owns 26,423 shares of the company's stock worth $4,036,000 after buying an additional 80 shares in the last quarter. V Square Quantitative Management LLC lifted its position in Johnson & Johnson by 0.5% during the second quarter. V Square Quantitative Management LLC now owns 49,542 shares of the company's stock worth $7,568,000 after purchasing an additional 257 shares during the period. Sound Income Strategies LLC grew its stake in Johnson & Johnson by 9.9% during the second quarter. Sound Income Strategies LLC now owns 6,800 shares of the company's stock worth $1,039,000 after buying an additional 611 shares in the last quarter. Jackson Grant Investment Advisers Inc. increased its holdings in Johnson & Johnson by 0.6% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 13,048 shares of the company's stock valued at $1,993,000 after buying an additional 78 shares during the period. Finally, Norris Perne & French LLP MI raised its position in shares of Johnson & Johnson by 2.3% in the 2nd quarter. Norris Perne & French LLP MI now owns 191,636 shares of the company's stock valued at $29,272,000 after buying an additional 4,232 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $181.63 on Tuesday. The stock has a 50-day moving average of $174.76 and a 200-day moving average of $162.18. The company has a market cap of $437.43 billion, a PE ratio of 19.43, a P/E/G ratio of 2.29 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.87.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the prior year, the business posted $2.82 EPS. The business's revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages have commented on JNJ. Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Morgan Stanley upped their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. UBS Group raised their target price on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. JPMorgan Chase & Co. boosted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 16th. Finally, Bank of America increased their target price on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $181.40.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.